Dr. Diaz on Response Rates With Pembrolizumab for CRC

Luis A. Diaz, MD
Published: Wednesday, Aug 02, 2017



Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the response rates of pembrolizumab (Keytruda) for patients with colorectal cancer (CRC).

The KEYNOTE-177 trial demonstrates that, in CRC and non-CRC, response rates with pembrolizumab are quite impressive. The progression-free survival and overall survival are quite durable, and it's recapitulated in entirely different studies, explains Diaz.

According to Diaz, what's impressive about the FDA approval is that it is not only across all tumor types, but it is in adults and children. This FDA approval has the potential to knock down the walls of how we think about cancer in the future, states Diaz.



Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the response rates of pembrolizumab (Keytruda) for patients with colorectal cancer (CRC).

The KEYNOTE-177 trial demonstrates that, in CRC and non-CRC, response rates with pembrolizumab are quite impressive. The progression-free survival and overall survival are quite durable, and it's recapitulated in entirely different studies, explains Diaz.

According to Diaz, what's impressive about the FDA approval is that it is not only across all tumor types, but it is in adults and children. This FDA approval has the potential to knock down the walls of how we think about cancer in the future, states Diaz.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x